NO20061419L - Triaza-spiropiperidinderivater for anvendelse som Glyt-1-inhibitorer i behandling av nevrologiske og nevropsykiatriske lidelser - Google Patents
Triaza-spiropiperidinderivater for anvendelse som Glyt-1-inhibitorer i behandling av nevrologiske og nevropsykiatriske lidelserInfo
- Publication number
- NO20061419L NO20061419L NO20061419A NO20061419A NO20061419L NO 20061419 L NO20061419 L NO 20061419L NO 20061419 A NO20061419 A NO 20061419A NO 20061419 A NO20061419 A NO 20061419A NO 20061419 L NO20061419 L NO 20061419L
- Authority
- NO
- Norway
- Prior art keywords
- lower alkyl
- hydrogen
- trifluoromethyl
- halogen
- group
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03024415 | 2003-10-23 | ||
| PCT/EP2004/011552 WO2005040166A1 (en) | 2003-10-23 | 2004-10-14 | Triaza-spiropiperidine derivatives for use as glyt-1 inhibitors in the treatment of neurological and neuropsychiatric disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20061419L true NO20061419L (no) | 2006-07-14 |
Family
ID=34486099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20061419A NO20061419L (no) | 2003-10-23 | 2006-03-28 | Triaza-spiropiperidinderivater for anvendelse som Glyt-1-inhibitorer i behandling av nevrologiske og nevropsykiatriske lidelser |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7189850B2 (de) |
| EP (1) | EP1678177B1 (de) |
| JP (1) | JP4490434B2 (de) |
| KR (1) | KR100798161B1 (de) |
| CN (1) | CN100467468C (de) |
| AR (1) | AR046186A1 (de) |
| AU (1) | AU2004283843B2 (de) |
| BR (1) | BRPI0415833A (de) |
| CA (1) | CA2543308C (de) |
| CO (1) | CO5690643A2 (de) |
| DE (1) | DE602004010419T2 (de) |
| ES (1) | ES2297502T3 (de) |
| IL (1) | IL174734A (de) |
| MX (1) | MXPA06004305A (de) |
| NO (1) | NO20061419L (de) |
| RU (1) | RU2006117368A (de) |
| TW (1) | TW200526662A (de) |
| WO (1) | WO2005040166A1 (de) |
| ZA (1) | ZA200603221B (de) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8492418B2 (en) | 2005-04-11 | 2013-07-23 | Yale University | Method of treating schizophrenia prodrome |
| DE102005038141A1 (de) * | 2005-08-12 | 2007-02-15 | Grünenthal GmbH | Substituierte 8-(3-Aminopropyl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-on-Derivate |
| CN101395142B (zh) * | 2006-03-08 | 2012-03-28 | 弗·哈夫曼-拉罗切有限公司 | 4-氨基-1,5-取代的1,5-二氢-咪唑-2-酮 |
| WO2007104776A1 (en) * | 2006-03-16 | 2007-09-20 | Glaxo Group Limited | N-phenyl-2-0x0-1,4-diazaspir0 [4.5] dec-3-en-1-yl acetamide derivatives and their use as glycine transporter inhibitors |
| GB0607398D0 (en) * | 2006-04-12 | 2006-05-24 | Glaxo Group Ltd | Compounds |
| AR061522A1 (es) * | 2006-06-20 | 2008-09-03 | Wyeth Corp | Derivados de 4-oxo-1, 3, 8-triaza[4.5]decanos como inhibidores del canal de potasio kv1.5, una composicion que los comprende y su empleo en el tratamiento de afecciones cardiacas. |
| JP2010517963A (ja) * | 2007-02-01 | 2010-05-27 | グラクソ グループ リミテッド | 神経学的および神経精神病学的障害の治療におけるＧｌｙＴ１トランスポーター阻害薬としての８−オキサ−１，４−ジアザスピロ［４，５］デク−３−エン−１−イルおよび１，４，８−トリアザスピロ［４，５］デク−３−エン−１−イルアセトアミド誘導体 |
| GB0701955D0 (en) * | 2007-02-01 | 2007-03-14 | Glaxo Group Ltd | Compounds |
| JP2010517961A (ja) * | 2007-02-01 | 2010-05-27 | グラクソ グループ リミテッド | ＧｌｙＴ１トランスポーター阻害薬および神経学的および神経精神病学的障害の治療におけるその使用 |
| GB0701985D0 (en) * | 2007-02-01 | 2007-03-14 | Glaxo Group Ltd | Compounds |
| AR065095A1 (es) * | 2007-02-01 | 2009-05-13 | Glaxo Group Ltd | COMPUESTO DE ARIL-OXO-DIAZAESPIRO, INTERMEDIARIO PARA SU SíNTESIS, USO DEL MISMO PARA PREPARAR UN MEDICAMENTO PARA EL TRATAMIENTO DE UN TRASTORNO MEDIADO POR GLYT1, COMPOSICION FARMACEUTICA Y ASOCIACION QUE LO COMPRENDEN. |
| EP2121624A1 (de) * | 2007-02-01 | 2009-11-25 | Glaxo Group Limited | Glyt1-transporter-hemmer und ihre verwendungen bei der behandlung von neurologischen und neuropsychiatrischen erkrankungen |
| WO2008092876A1 (en) * | 2007-02-01 | 2008-08-07 | Glaxo Group Limited | Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders |
| CN101686672A (zh) | 2007-05-31 | 2010-03-31 | 塞普拉柯公司 | 苯基取代的环烷胺作为一元胺再摄取抑制剂 |
| KR101150628B1 (ko) | 2007-07-03 | 2012-05-31 | 에프. 호프만-라 로슈 아게 | 4-이미다졸린 및 항우울제로서 이의 용도 |
| WO2009024611A2 (en) | 2007-08-22 | 2009-02-26 | Abbott Gmbh & Co. Kg | 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use |
| WO2009034062A1 (en) * | 2007-09-11 | 2009-03-19 | Glaxo Group Limited | Compounds which inhibit the glycine transporter and uses thereof in medicine |
| US9413889B2 (en) * | 2007-09-18 | 2016-08-09 | Telecommunication Systems, Inc. | House number normalization for master street address guide (MSAG) address matching |
| US7981904B2 (en) * | 2008-03-20 | 2011-07-19 | Takeda Pharmaceutical Company Limited | Acetyl CoA carboxylase inhibitors |
| EP2271625B1 (de) | 2008-04-01 | 2012-09-12 | Abbott GmbH & Co. KG | Tetrahydroisochinoline, pharmazeutische zusammensetzungen damit und ihre therapeutische verwendung |
| CA2746967A1 (en) * | 2009-01-27 | 2010-08-05 | F. Hoffmann-La Roche Ag | Aroylamino - and heteroaroylamino-substituted piperidines as glyt-1 inhibitors |
| TW201038569A (en) | 2009-02-16 | 2010-11-01 | Abbott Gmbh & Co Kg | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy |
| AR075442A1 (es) | 2009-02-16 | 2011-03-30 | Abbott Gmbh & Co Kg | Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia |
| US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| US8846743B2 (en) | 2010-08-13 | 2014-09-30 | Abbott Laboratories | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8877794B2 (en) | 2010-08-13 | 2014-11-04 | Abbott Laboratories | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9051280B2 (en) | 2010-08-13 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9045459B2 (en) | 2010-08-13 | 2015-06-02 | AbbVie Deutschland GmbH & Co. KG | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8883839B2 (en) | 2010-08-13 | 2014-11-11 | Abbott Laboratories | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| SG10201508715YA (en) | 2010-10-25 | 2015-11-27 | G1 Therapeutics Inc | Cdk inhibitors |
| US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
| US9309200B2 (en) | 2011-05-12 | 2016-04-12 | AbbVie Deutschland GmbH & Co. KG | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| WO2013020930A1 (en) | 2011-08-05 | 2013-02-14 | Abbott Gmbh & Co. Kg | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8846741B2 (en) | 2011-11-18 | 2014-09-30 | Abbvie Inc. | N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| EP2831080B1 (de) | 2012-03-29 | 2017-03-15 | Francis Xavier Tavares | Lactamkinaseinhibitoren |
| JP2015157764A (ja) * | 2012-06-14 | 2015-09-03 | 大正製薬株式会社 | グリシントランスポーター阻害物質 |
| EP2967050A4 (de) | 2013-03-15 | 2016-09-28 | G1 Therapeutics Inc | Hochaktive antineoplastische und antiproliferative mittel |
| EP2968291B1 (de) | 2013-03-15 | 2025-04-16 | Pharmacosmos Holding A/S | Hspc-schonende behandlungen für rb-positive abnormale zelluläre proliferation |
| US9650334B2 (en) | 2013-03-15 | 2017-05-16 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9656955B2 (en) | 2013-03-15 | 2017-05-23 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| CA2924689A1 (en) | 2013-10-17 | 2015-04-23 | AbbVie Deutschland GmbH & Co. KG | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| CN105764895A (zh) | 2013-10-17 | 2016-07-13 | 艾伯维德国有限责任两合公司 | 氨基四氢化萘及氨基二氢化茚衍生物，包含其的药物组合物及其在治疗中的用途 |
| AU2014374043B2 (en) | 2014-01-06 | 2019-06-27 | Algomedix, Inc. | TRPA1 modulators |
| US9717735B2 (en) | 2014-04-17 | 2017-08-01 | G1 Therapeutics, Inc. | Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation |
| US9708334B2 (en) | 2014-04-24 | 2017-07-18 | Dart Neuroscience (Cayman) Ltd. | Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine compounds as GlyT1 inhibitors |
| US9550754B2 (en) | 2014-09-11 | 2017-01-24 | AbbVie Deutschland GmbH & Co. KG | 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy |
| WO2016040858A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| US10040759B2 (en) | 2014-11-05 | 2018-08-07 | Dart Neuroscience (Cayman) Ltd. | Substituted azetidinyl compounds as GlyT1 inhibitors |
| BR112018015389B1 (pt) | 2016-03-17 | 2023-12-19 | F. Hoffmann-La Roche Ag | Derivado de 5-etil-4-metil-pirazol-3-carboxamida, seu processo de fabricação, preparação farmacêutica oral e uso |
| WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| AU2018205262A1 (en) | 2017-01-06 | 2019-07-11 | G1 Therapeutics, Inc. | Combination therapy for the treatment of cancer |
| MX392531B (es) | 2017-06-29 | 2025-03-24 | G1 Therapeutics Inc | Formas morficas de g1t38 y metodos de preparacion de las mismas. |
| CN120817904A (zh) | 2018-08-24 | 2025-10-21 | 法码科思莫斯有限公司 | 1,4-二氮杂螺[5.5]十一烷-3-酮改进的合成 |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2170446T3 (es) * | 1997-12-05 | 2002-08-01 | Hoffmann La Roche | Derivados de 1,3,8-triaza-espiro(4,5)decan-4-ona. |
| EP0921125B1 (de) * | 1997-12-05 | 2002-01-30 | F. Hoffmann-La Roche Ag | 1,3,8-Triazaspiro[4,5]decan-4-on-derivate |
| EP1594840B1 (de) * | 2003-02-17 | 2006-09-27 | F. Hoffmann-La Roche Ag | Piperidinbenzolsulfonamidderivate |
-
2004
- 2004-10-14 BR BRPI0415833-4A patent/BRPI0415833A/pt not_active IP Right Cessation
- 2004-10-14 ES ES04790408T patent/ES2297502T3/es not_active Expired - Lifetime
- 2004-10-14 KR KR1020067007791A patent/KR100798161B1/ko not_active Expired - Fee Related
- 2004-10-14 EP EP04790408A patent/EP1678177B1/de not_active Expired - Lifetime
- 2004-10-14 DE DE602004010419T patent/DE602004010419T2/de not_active Expired - Lifetime
- 2004-10-14 RU RU2006117368/04A patent/RU2006117368A/ru not_active Application Discontinuation
- 2004-10-14 AU AU2004283843A patent/AU2004283843B2/en not_active Ceased
- 2004-10-14 WO PCT/EP2004/011552 patent/WO2005040166A1/en not_active Ceased
- 2004-10-14 CA CA2543308A patent/CA2543308C/en not_active Expired - Fee Related
- 2004-10-14 MX MXPA06004305A patent/MXPA06004305A/es active IP Right Grant
- 2004-10-14 JP JP2006536007A patent/JP4490434B2/ja not_active Expired - Fee Related
- 2004-10-14 CN CNB2004800309109A patent/CN100467468C/zh not_active Expired - Fee Related
- 2004-10-18 US US10/967,534 patent/US7189850B2/en not_active Expired - Fee Related
- 2004-10-20 TW TW093131857A patent/TW200526662A/zh unknown
- 2004-10-21 AR ARP040103809A patent/AR046186A1/es not_active Application Discontinuation
-
2006
- 2006-03-28 NO NO20061419A patent/NO20061419L/no not_active Application Discontinuation
- 2006-04-03 IL IL174734A patent/IL174734A/en not_active IP Right Cessation
- 2006-04-21 ZA ZA200603221A patent/ZA200603221B/xx unknown
- 2006-05-03 CO CO06041532A patent/CO5690643A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2543308C (en) | 2012-03-06 |
| CA2543308A1 (en) | 2005-05-06 |
| JP2007509097A (ja) | 2007-04-12 |
| KR20060076317A (ko) | 2006-07-04 |
| WO2005040166A1 (en) | 2005-05-06 |
| CN1871238A (zh) | 2006-11-29 |
| AU2004283843B2 (en) | 2010-04-22 |
| AR046186A1 (es) | 2005-11-30 |
| IL174734A0 (en) | 2006-08-20 |
| EP1678177B1 (de) | 2007-11-28 |
| CN100467468C (zh) | 2009-03-11 |
| ES2297502T3 (es) | 2008-05-01 |
| KR100798161B1 (ko) | 2008-01-28 |
| EP1678177A1 (de) | 2006-07-12 |
| RU2006117368A (ru) | 2007-12-10 |
| CO5690643A2 (es) | 2006-10-31 |
| DE602004010419T2 (de) | 2008-10-09 |
| BRPI0415833A (pt) | 2007-01-02 |
| IL174734A (en) | 2010-05-31 |
| AU2004283843A1 (en) | 2005-05-06 |
| ZA200603221B (en) | 2009-04-29 |
| DE602004010419D1 (de) | 2008-01-10 |
| JP4490434B2 (ja) | 2010-06-23 |
| US20050107373A1 (en) | 2005-05-19 |
| MXPA06004305A (es) | 2006-06-05 |
| US7189850B2 (en) | 2007-03-13 |
| TW200526662A (en) | 2005-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20061419L (no) | Triaza-spiropiperidinderivater for anvendelse som Glyt-1-inhibitorer i behandling av nevrologiske og nevropsykiatriske lidelser | |
| NO20060975L (no) | 1-Benzoyl-piperazinderivater som glycin gjenopptaksinhibitorer for behandling av psykoser | |
| Alagarsamy et al. | Synthesis and pharmacological investigation of novel 4-benzyl-1-substituted-4H-[1, 2, 4] triazolo [4, 3-a] quinazolin-5-ones as new class of H1-antihistaminic agents | |
| TW200505907A (en) | Piperidine-benzenesulfonamide derivatives | |
| NO20073667L (no) | [4-(heteroaryl) piperazin-1-yl]-(2,5-substituert-fenyl)metanonderivater som glycintransportor 1(GLYT-1)- inhibitorer for behandling av neurologiske og neuropsykiatriske lidelser | |
| AU611997B2 (en) | 3,4 amino quinolines and 4 amino 3 nitroquinolines | |
| DK2297120T3 (en) | Aminodihydrothiazine derivatives as bace inhibitors for the treatment of Alzheimer's disease | |
| SE0202134D0 (sv) | Therapeutic agents | |
| NO20072833L (no) | Bi- og tricykliske substituterte fenylmetanoner som glycinetransportor I-(Glyt-1)-inhibitorer for behandling av Alzheimers sykdom | |
| NO20015686L (no) | Nye forbindelser, deres anvendelse og fremstilling | |
| NZ532494A (en) | Dibenzylamine compound and medicinal use thereof | |
| PE20071009A1 (es) | Compuestos derivados de fenoxipiperidinas como antagonistas de histamina h3 | |
| JP2002504484A (ja) | 新規化合物 | |
| NO20081056L (no) | Nye, heterosykliske NF-kB-inhibitorer | |
| DE69835877D1 (de) | Trizyklische verbindungen | |
| JP2011510972A5 (de) | ||
| CA2488761A1 (en) | 2-benzofuryl or benzothiophenyl-quinuclidinyl amides as nicotinic acetylcholine receptor inhibitors | |
| HU203233B (en) | Process for producing aryl piperazinyl alkoxy derivatives of cyclic imides and pharmaceutical compositions comprising such compounds | |
| RU2008148165A (ru) | Замещенные производные фенилметанона | |
| AU2004215523B2 (en) | Method for Preparing Acid Addition Salts of Polyacidic Basic Compounds | |
| WO2007054444A3 (en) | 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives | |
| NZ243340A (en) | 2-aminopyrimidine-4-carboxamide derivatives, pharmaceutical compositions | |
| US4677104A (en) | Antipsychotic fused-ring pyridinylpiperazine derivatives | |
| Alagarsamy et al. | Synthesis of 4-butyl-1-substituted-4H-[1, 2, 4] triazolo [4, 3-a] quinazolin-5-ones as new class of H1-antihistaminic agents | |
| NO20070972L (no) | Benzyloksyderivater som MAOB-inhibitorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |